Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

One In Three Detected Breast Cancers Is Overdiagnosed
Researchers conclude in a paper just published on bmj.com that one in three breast cancers detected in a population with a public breast screening program is overdiagnosed.
generic viagra online
Employee Involvement Programs Key To Workplace Diversity
A new study by a University of Arizona professor shows employee involvement programs that executives adopt to increase efficiency also end up improving their record on diversity.
News of the day
MADIT-CRT Trial Meets Primary Endpoint
Boston Scientific Corporation (NYSE: BSX) and the University of Rochester Medical Center announced that the landmark MADIT-CRT trial has met its primary endpoint. Preliminary results show Boston Scientific cardiac resynchronization therapy defibrillators (CRT-Ds) to be associated with a significant 29 percent reduction (p=0.003) in death or heart failure interventions when compared to traditional implantable cardioverter defibrillators (ICDs). High risk(1), asymptomatic or mildly symptomatic, New York Heart Association (NYHA) Class I and II(2) patients were enrolled in MADIT-CRT. The MADIT-CRT Executive Committee expects to present and publish the trial"s full results later this year.
Health Insurance

Oncologic Drugs Advisory Committee Meeting Set By FDA

Medical Industry E-Mail News Service™ -- July 07 2009 -- The US Food & Drug Administration (FDA) has announced that its Oncologic Drugs Advisory Committee will meet on July 15 2009, in Gaithersburg MD, to discuss (1) new drug application (NDA) 022-447, proposed trade name Yondelis (trabectedin) powder, for concentrate for solution for intravenous infusion, Centocor Ortho Biotech Products, L.P., proposed indication in combination with Doxcil (doxorubicin HCl liposome injection), for treating patients with relapsed ovarian cancer; and (2) supplemental new drug application (sNDA) 050-718/S-039, Doxil (doxorubicin HCl liposome injection), for intravenous infusion, Centocor Ortho Biotech Products, L.P., proposed indication in combination with docetaxel for treating patients with locally advanced or metasatic breast cancer who have received prior anthracycline treatment. There is no charge to attend. When & Where July 15 2009; 8 am-5 pm Hilton Washington DC N/Gaithersburg Ballrooms 620 Perry Pkwy Gaithersburg MD FDA Center for Drug Evaluation & Research (HFD-21)


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009